{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:12:46Z","timestamp":1791324766566,"version":"4.3.1"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0058975","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T22:41:25Z","timestamp":1363992085000},"page":"e58975","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States"],"prefix":"10.1371","volume":"8","author":[{"given":"Shan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holodniy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, Management, and Treatment of Hepatitis C: An Update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"KN Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"GL Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","article-title":"Hepatitis C virus testing of persons born during 1945\u20131965: recommendations from the Centers for Disease Control and Prevention","volume":"157","author":"BD Smith","year":"2012","journal-title":"Ann of Intern Med"},{"key":"ref5","unstructured":"NIH Consensus Development Program website. National Institutes of Health Consensus Statement on Management of hepatitis C: 2002. June 10\u201312; 19(3) 1\u201346. Available: http:\/\/consensus.nih.gov\/2002\/2002HepatitisC2002116main.htm<\/ext-link>. Accessed 2009 October 1."},{"key":"ref6","unstructured":"ALF website. American Liver Foundation Position. Available: http:\/\/www.liverfoundation.org\/about\/advocacy\/hcvscreening\/#AASLD<\/ext-link>. Accessed 2011 November 1."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/0003-4819-140-6-200403160-00014","article-title":"Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force","volume":"140","author":"R Chou","year":"2004","journal-title":"Ann of Intern Med"},{"key":"ref8","unstructured":"USPSTF website. USPSTF Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement DRAFT. Available: http:\/\/www.uspreventiveservicestaskforce.org\/uspstf12\/hepc\/hepcdraftrec.htm<\/ext-link>. Accessed 2013 February 26."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for Untreated Chronic HCV Genotype 1 Infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0002-9343(01)00951-2","article-title":"Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults","volume":"111","author":"ME Singer","year":"2001","journal-title":"American Journal of Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"DB Rein","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref13","first-page":"1259","article-title":"Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis","volume":"54","author":"PO Coffin","year":"2012"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","article-title":"Economic model of a birth cohort screening program for hepatitis C virus","volume":"55","author":"LJ McGarry","year":"2011","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"S Liu","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwf100","article-title":"Empirically calibrated model of hepatitis C virus infection in the United States","volume":"156","author":"JA Salomon","year":"2002","journal-title":"American Journal of Epidemiology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1572-0241.2007.01522.x","article-title":"Outcome of screening for hepatitis C virus infection based on risk factors","volume":"103","author":"C Mallette","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression","volume":"48","author":"HH Thein","year":"2008","journal-title":"Hepatology"},{"key":"ref19","unstructured":"Arias E National Vital Statistics Reports, United States Life Tables, 2006. Center for Disease Control, Division of Vital Statistics."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jhep.2010.08.035","article-title":"Trends in mortality after diagnosis of hepatitis B or C infection: 1992\u20132006","volume":"54","author":"SR Walter","year":"2011","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population","volume":"53","author":"SS El-Kamary","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2893.2011.01476.x","article-title":"Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis","volume":"18","author":"V Di Martino","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, et al<\/etal>.. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9: 509\u2013516 e501.","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/archinte.160.11.1665","article-title":"Screening for hepatitis C virus in a health maintenance organization","volume":"160","author":"LR Fischer","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2893.2006.00763.x","article-title":"Treatment rates in patients with chronic hepatitis C after liver biopsy","volume":"13","author":"G Narasimhan","year":"2006","journal-title":"Journal of Viral Hepatitis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1524-4733.2009.00691.x","article-title":"Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population","volume":"13","author":"D Mitra","year":"2010","journal-title":"Value in Health"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e26783","DOI":"10.1371\/journal.pone.0026783","article-title":"Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients","volume":"6","author":"S Liu","year":"2011","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/MLR.0b013e31803dce05","article-title":"Quality-of-life weights for the US population - Self-reported health status and priority health conditions, by demographic characteristics","volume":"45","author":"JA Nyman","year":"2007","journal-title":"Medical Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"PW Sullivan","year":"2006","journal-title":"Medical Decision Making"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population","volume":"290","author":"JA Salomon","year":"2003","journal-title":"Jama-Journal of the American Medical Association"},{"key":"ref31","first-page":"1332","article-title":"Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C. Gut","volume":"55","author":"R Grieve","year":"2006"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.164.21.2377","article-title":"Health values of patients with chronic hepatitis C infection","volume":"164","author":"KE Sherman","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"CAKY Chong","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: A systematic review","volume":"28","author":"DJ McLernon","year":"2008","journal-title":"Medical Decision Making"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.510300504","article-title":"The impact of diagnosis of hepatitis C virus on quality of life","volume":"30","author":"AJ Rodger","year":"1999","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1377\/hlthaff.23.4.176","article-title":"Trends in medical spending by age, 1963\u20132000","volume":"23","author":"E Meara","year":"2004","journal-title":"Health Affairs"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/109350702320229195","article-title":"Cost Burden of Illness for Hepatitis C Patients with Employer-Sponsored Health Insurance","volume":"5","author":"AW Poret","year":"2002","journal-title":"Disease Management"},{"key":"ref38","unstructured":"Bureau of Labor Statistics website. May 2010 National Occupational Employment and Wage Estimates United States. Available: http:\/\/www.bls.gov\/oes\/2010\/may\/oes_nat.htm<\/ext-link>. Accessed 2011 January 1."},{"key":"ref39","unstructured":"U.S. Department Of Labor, Bureau of Labor Statistics Consumer Price Index. Available: ftp:\/\/ftp.bls.gov\/pub\/special.requests\/cpi\/cpiai.txt<\/ext-link>. Accessed 2010 June 1."},{"key":"ref40","unstructured":"U.S. Census Bureau website. U.S. Census 2009 Population Estimates National Characteristics. Available: http:\/\/www.census.gov\/popest\/data\/national\/asrh\/2009\/index.html<\/ext-link>. Accessed 2012 March 1."},{"key":"ref41","unstructured":"Gold MR (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press. xxiii, 425 p. p."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s12072-008-9086-x","article-title":"Demographics of a large cohort of urban chronic hepatitis C patients","volume":"2","author":"FA Siddiqui","year":"2008","journal-title":"Hepatology International"},{"key":"ref43","unstructured":"Heeswijk RV, Vandevoorde A, Boogaerts G, Vangeneugden T, Paepe E, et al<\/etal>.. (2011) Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston. February 27\u2013March 2, 2011. Abstract 119. Available: http:\/\/www.retroconference.org\/2011\/Abstracts\/41437.htm<\/ext-link>. Accessed 2013 January 1."},{"key":"ref44","unstructured":"Kasserra C, Hughes E, Treitel M, Gupta S, O\u2019Mara E (2011) Clinical Pharmacology of BOC: Metabolism, Excretion, and Drug-Drug Interactions. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston. February 27\u2013March 2, 2011. Abstract 118. Available: http:\/\/www.retroconference.org\/2011\/Abstracts\/41140.htm<\/ext-link>. Accessed 2013 January 1."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","article-title":"Incidence and transmission patterns of acute hepatitis C in the United States, 1982\u20132006","volume":"171","author":"IT Williams","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus","volume":"139","author":"AJ Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref47","first-page":"43S","article-title":"Diagnostic tests for hepatitis C. Hepatology","volume":"26","author":"DR Gretch","year":"1997"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-3148.1992.tb00157.x","article-title":"Predictive markers for hepatitis C antibody ELISA specificity in Australian blood donors","volume":"2","author":"CA Hyland","year":"1992","journal-title":"Transfus Med"},{"key":"ref49","first-page":"460","article-title":"Cost-effectiveness of screening and vaccinating Asian and pacific islander adults for hepatitis B. Ann of Intern Med","volume":"147","author":"DW Hutton","year":"2007"},{"key":"ref50","unstructured":"United Network for Organ Sharing website. Available: http:\/\/www.unos.org\/<\/ext-link>. Accessed 2011 January 1."},{"key":"ref51","unstructured":"National Cancer Institute website. SEER Cancer Stat Fact Sheets. Available: http:\/\/seer.cancer.gov\/statfacts\/<\/ext-link>. Accessed 2011 April 3."},{"key":"ref52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","article-title":"A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon","volume":"24","author":"G Fattovich","year":"1996","journal-title":"Journal of Hepatology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1155\/2000\/107982","article-title":"Appropriateness of liver biopsy","volume":"14","author":"T Poynard","year":"2000","journal-title":"Canadian Journal of Gastroenterology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection","volume":"361","author":"JG McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"ref55","first-page":"645","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology","volume":"38","author":"GL Davis","year":"2003"},{"key":"ref56","unstructured":"Merck (2011) FDA Antiviral Drugs Advisory Committee Meeting Boceprevir Capsules (NDA 202\u2013258) Briefing Document. Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252343.pdf<\/ext-link>. Accessed May 15."},{"key":"ref57","unstructured":"Vertex Pharmaceuticals (2011) Telaprevir 375-mg Film-Coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C, Antiviral Drugs Advisory Committee Briefing Document (Telaprevir NDA 201\u2013917). Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252562.pdf<\/ext-link>. Accessed May 15."},{"key":"ref58","unstructured":"Birnkrant D, Team TR (2011) Advisory Committee Briefing Document for NDA 201\u2013917 Telaprevir 375 mg tablets. Silver Spring: Department of Health & Human Services, Public Health Service, Food and Drug Administration. Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252561.pdf<\/ext-link>. Accessed 1 May 2011."},{"key":"ref59","unstructured":"NATAP website. Levin J. Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Na\u00efve patients: Final results of Phase 3 ADVANCE Study 2010; Boston, MA, Hynes Convention Center. Available: http:\/\/www.natap.org\/2010\/AASLD\/AASLD_23.htm<\/ext-link>. Accessed 1 March 2011."},{"key":"ref60","unstructured":"Background Materials for Boceprevir Advisory Committee Division of Antiviral Products (DAVP). Available: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/AntiviralDrugsAdvisoryCommittee\/ucm252341.pdf<\/ext-link>. Accessed 2011 May 15."},{"key":"ref61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/00333549081230S307","article-title":"Comparing the costs of HIV screening strategies and technologies in health-care settings","volume":"123","author":"PG Farnham","year":"2008","journal-title":"Public Health Rep"},{"key":"ref62","unstructured":"Thomson Corporation. (2009) Red book: pharmacy's fundamental reference. Montvale, NJ: Thomson PDR. pp. v."},{"key":"ref63","unstructured":"The New York Times website. Pollack A (2011) Second Drug Wins Approval for Treatment of Hepatitis C. Available: http:\/\/www.nytimes.com\/2011\/05\/24\/business\/24drug.html?_r=1<\/ext-link>.Accessed 2011 June 1."},{"key":"ref64","unstructured":"United States Department of Veterans Affairs website. Federal Supply Schedule, Drug Pharmaceutical Prices 2011. Available: http:\/\/www.pbm.va.gov\/DrugPharmaceuticalPrices.aspx<\/ext-link>. Accessed 2011 June 24."},{"key":"ref65","unstructured":"Stephens CJM, Carter J, Gao X, Haider S, Rustgi VK. Adverse Event-Related Treatment Costs Associated with Protease Inhibitor-Based Combination Therapy for Hepatitis C; 2010 September 6, 2010. AASLD ePoster. Available: http:\/\/trs.scivee.tv\/node\/4033?destination=node%2F4033<\/ext-link>. Accessed 2012 December 1."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/030079904125003485","article-title":"Burden of illness of hepatitis C from a managed care organization perspective","volume":"20","author":"EP Armstrong","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, et al<\/etal>.. (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann of Intern Med 127: 855\u2013&.","DOI":"10.7326\/0003-4819-127-10-199711150-00001"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0058975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T05:40:49Z","timestamp":1644644449000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0058975"}},"subtitle":[],"editor":[{"given":"Erica","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0058975","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}